beyond the tumor

beyond the tumor

beyond the tumor

beyond the tumor

Our mission

To translate the predictive power of proteomics into improved, truly personalized care that makes a real difference in the lives of cancer patients worldwide.

Who we are

OncoHost is a precision diagnostics company headquartered in Binyamina, Israel and Cary, NC. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1500 patients recruited worldwide, OncoHost aims to understand the patient's unique response to therapy to overcome one of the major obstacles in clinical oncology today – resistance to treatment.

Supported by robust clinical evidence, strong IP positioning, and first-mover advantage, OncoHost has developed the PROphet® platform. Combining bioinformatics, system biology, proteomic pattern recognition and machine learning, PROphet® provides clinicians with actionable clinical insights, optimal choice of therapy, and a better understanding of a
patient’s personalized cancer dynamics.


Ofer Sharon, MD

Dr. Ofer Sharon is a physician and entrepreneur with 20 years of experience in clinical and commercial product development for startups in the health tech, biotech, and medical device industries. Prior to joining OncoHost, he served multiple roles in global pharmaceutical companies including Medical Director for AstraZeneca (Israel), new technologies scout for MedImmune, and Medical Director for MSD (Israel). He co-founded several healthcare companies, mainly focusing on bioinformatic and machine-learning platforms for clinical deterioration detection and early intervention. Dr. Sharon is a Major (res.) in the IDF and a medical company commander specializing in disaster relief. He received his MD cum laude from Tel Aviv University, Israel.

Steven Gottlieb, MD

Steven M. Gottlieb, M.D. is a physician executive and healthcare serial entrepreneur with over 30 years of experience in the healthcare industry. He completed his specialty training in anesthesiology, pain management, and critical care medicine at The Johns Hopkins Hospital. He has founded, managed, funded, grown and exited several successful healthcare companies.

Dr. Gottlieb has served on numerous boards of directors and in various leadership positions within hospital, community, corporate and professional organizations. His board positions (chairman, member or advisory) have included Medical Center Boards of Trustees, County Board of Health, EGPG, Anthem Associates, Anesthetix Holdings, Billing Management, Coagulo Medical Technologies, TruVue Analytics, Katao Venture Partners, Temple University, First City Bank of Commerce and the Palm Beach Round Table.

Dr. Gottlieb has led or participated in a range of successful investments in a variety of growth companies, both inside and outside of the healthcare industry. Dr. Gottlieb currently serves as Chairman of Javelin10x, an organization that functions as a strategic operating partner to entrepreneurial companies and helps accelerate their growth and success.

Yuval Shaked, PhD

Co-Founder &
Chief Scientific Advisor
Prof. Yuval Shaked leads an academic research laboratory at the Rappaport Faculty of Medicine of the Technion – Israel Institute of Technology. His pioneering research, which focuses on understanding tumor-host interactions and therapy-induced mechanisms of tumor progression, serves as the scientific basis for OncoHost’s technology. Prof. Shaked is currently head of the Technion Integrated Cancer Center and President of the International Cancer Microenvironment Society. Formerly, he served as Vice Dean for Research at the Rappaport Faculty of Medicine of the Technion. In addition, he is a member of several cancer societies, including the American Association for Cancer Research (AACR), the European Association of Cancer Research (EACR), and the Israel Society of Cancer Research (ISCR). Prof. Shaked is the author and co-author of over 100 peer-reviewed publications and 5 patents and a recipient of multiple competitive research grants including the prestigious European Research Council (ERC) grants. For his achievements, he has received numerous awards including the Igal Alon fellowship award for starting junior faculty, the Krill Prize for Excellence in Scientific Research, and the Youdim Family Prize for Excellence in Cancer Research. He received his Ph.D. in biochemistry from the Hebrew University of Jerusalem, Israel, and completed his post-doctoral training at Sunnybrook Health Sciences Centre, University of Toronto, Canada.

Adam Dicker, MD, PhD

Chief Medical Officer
Prof. Adam Dicker is a leading radiation oncologist, serving as Senior Vice President and Chair of Enterprise Radiation Oncology, Director of the Jefferson Institute for Digital Health, and Professor of Radiation Oncology and Pharmacology and Experimental Therapeutics at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC). For his significant contributions to oncology research, education and patient care, Prof. Dicker has been named Fellow of the American Society of Clinical Oncology (FASCO) and Fellow of the American Society for Radiation Oncology (FASTRO). Among his numerous leadership positions are: Chair of the AACR’s Radiation Oncology Section of the Clinical Research Subcommittee; Chair of the ASCO-ASTRO Radiation Oncology Panel; Co-chair of NRG Oncology’s Translational Science and Digital Health committees; Co-Chair of the NCI Radiation Oncology Working Group; Editorial board member for several peer-reviewed journals.

Galit Yahalom, PhD

VP Clinical and Regulatory Affairs
Dr. Galit Yahalom has over 15 years of experience in the biotechnology industry, with a proven track record in end-to-end diagnostic product development, including R&D, clinical studies and regulatory submissions. She was a co-founder of, consultant for and CTO of several biomedical diagnostic companies. Dr. Yahalom holds a PhD in molecular biology from the Weizmann Institute of Science.

Yehonatan Elon, PhD

Dr. Yehonatan Elon has over 10 years of experience in the data and algorithms industry, with a proven track record in end-to-end product development. Yehonatan holds a PhD in physics from the Weizmann Institute of Science, was director of new technologies at BrightSource Energy and VP of research at MeteoLogic and Feedvisor.

Michal Harel, PhD

Director of Science and Innovation
Dr. Michal Harel has over 8 years of experience in OMIC-level bioinformatic analysis, with strong expertise in working with proteomics data. Prior to joining OncoHost, Dr. Harel worked as a research associate at Tel Aviv University. She received her PhD from the Weizmann Institute of Science, followed by a post-doctoral period at the Technion – Israel Institute of Technology.

Shani Raveh Shoval, PhD

Intellectual Property Director
Dr. Shani Raveh Shoval has 15 years of experience in biological research and intellectual property. Prior to joining OncoHost, she was a project manager at Pluristem therapeutics and intellectual property manager at Enzymotec. Dr. Shoval holds a PhD in molecular and cellular biology from the Weizmann Institute of Science.

Itamar Sela, PhD

Dr. Itamar Sela is a multidisciplinary scientist specializing in mathematical modeling and data analysis, with extensive experience in physics and computational biology. Prior to joining OncoHost he was a postdoctoral fellow at the National Institutes of Health in Maryland USA, where he developed a theoretical framework to study quantitatively bacterial genome evolution. Dr. Sela received his PhD in theoretical physics from the Ben-Gurion University, followed by R&D positions in the industry and post-doctoral trainings.

Moti Hacham, LLB

Moti Hacham has more than 20 years of versatile senior management, operational, financial and legal experience in the biotech industry, including positions at Spero Bio (CEO), Avraham Pharma (CFO&COO), Polyheal (COO), CureTech (CFO) and Clal Life Sciences (CEO). Previously an attorney in a leading law firm, and assistant to the CFO of Check Point Software Technologies (NASDAQ: CHKP). Holds a BA in Economics from the Tel-Aviv University, and an LLB from the Bar-Ilan University. A member of the Israeli Bar Association.

Chris Dingman, MBA

Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.

Ayelet Ran

Head of Product
Ayelet has over 15 years of experience in leading medical system implementation, product management, business analysis, programming, and customer consulting in the healthcare industry. Prior to joining OncoHost, she was implementation lead at Algotec, professional services manager, product manager at EarlySign, and product and project manager at Kamet. Ayelet holds an ME in Biomedical Engineering from the Technion Institute of Technology.

Oshrit Regev Rokach

Head of HR

Scientific Advisory Board

Lee M. Ellis, MD, FACS, FASCO

Scientific Advisor
Dr. Ellis is the The Ruben Distinguished Chair in Gastroenterology Cancer Research and a professor in the Departments of Surgical Oncology, and Molecular & Cellular Oncology at MDACC. He previously served as interim chair, Department of Cancer Biology (2008-2012), Director of the Metastasis Research Center (2010-2012), and Director of the Colorectal Cancer (CRC) Translational Research Program (2007-2013) at MDACC. He is currently Executive Director for Translational Medicine for MDACC’s Global Academic Program. Dr. Ellis has an active research laboratory that is focused on the biology of colorectal cancer and therapeutic targets. Dr. Ellis is active at the national level by playing leadership roles in ASCO and the AACR. He is currently a member of the ASCO Board of Directors. Dr. Ellis was co-program director of the AACR annual meeting in 2009 and 2011, and has served as course co-director of the AACR/ASCO Methods in Clinical Cancer Research Workshop (Vail Course, 2012-2014) and is currently co-director for the EORTC-ESMO-AACR-ECCO Methods in Clinical Cancer Research Workshop. Dr. Ellis serves as Vice Chair of SWOG, Translational Medicine, and Vice Chair of the Hope Foundation, SWOG’s philanthropic arm. He is currently co-chair of the National Cancer Institute’s (NCI) National Clinical Trials Network Core Correlative Sciences Committee. Dr. Ellis is also on the board of directors for the Canines-N-Kids Foundation. He currently serves on the ECOG/ACRIN data safety monitoring committees and the Scientific Audit Committee of the EORTC (Brussels, Belgium). Dr. Ellis is a Deputy Editor for JAMA Oncology.

David Carbone, MD, PhD

Clinical Advisor
David Carbone is Professor of Internal Medicine, Director of the James Thoracic Oncology Center at the OSUMC. He graduated summa cum laude from Amherst College in 1977 and received an MD and a PhD in Molecular Biology and Genetics at Johns Hopkins University in 1985. After an Internal Medicine internship and residency at The Johns Hopkins Hospital, he did a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. At Vanderbilt he was Director of the Thoracic/Head and Neck Cancer Program, Director of a SPORE in Lung Cancer for 11 years. He was recruited to The Ohio State University in 2012 to direct the James Thoracic Oncology Center. His research interests have been focused on lung cancer and specifically proteomic and expression signature development, lung cancer genetics, tumor-associated immunosuppression mechanisms, proteogenomic profiling of lung cancers to guide the development of novel therapeutics, and targeting novel immunosuppression mechanisms. He has over 250 peer-reviewed publications, has served on the Board of Scientific Counselors, and has continuous NCI funding since early in his career. He is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and Past-President of the International Association for the Study of Lung Cancer (IASLC).

Michal Lotem, MD

Clinical Advisor
Prof. Michal Lotem is a senior physician and researcher, serving as Head of the Center for Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah University Hospital, and senior lecturer at the Faculty of Medicine, Hebrew University of Jerusalem. In parallel to intensive clinical work, she runs a scientific translational research lab focusing on tumor vaccines and cell-based immunotherapies for melanoma. She has co-authored over 70 peer-reviewed publications and is a member of several medical societies including the Melanoma Research Alliance, Society of Melanoma Research, European Association of Cancer Research (EACR), Israel Society of Cancer Research (ISCR) and Committee for Cell and Gene-based Therapy of the Israeli Ministry of Health. Prof. Lotem received her MD from the Sackler Faculty of Medicine at the Tel Aviv University, Israel, and was a research fellow at the National Institute of Health (NIH), Maryland, USA.

Mario Sznol, MD

Scientific Advisor
Dr. Mario Sznol is a Professor of Internal Medicine, Leader of the Melanoma-Renal Cancer Disease-Associated Translational Research Team, and Co-Leader of the Cancer Immunology Program. Dr. Sznol is also the current President of the Society for Immunotherapy of Cancer (SITC). Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), and Cancer Therapy Evaluation Program of the National Cancer Institute. He was Head of the BES from 1994-1999. He attended on the inpatient units of the Biological Response Modifiers Program, NCI, from 1988-1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004, he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut. Dr. Sznol’s areas of interest include early drug development, immunotherapy, and treatments for advanced melanoma and renal cancer.

Aaron Ciechanover, MD, DSC

Scientific Advisor
Prof. Ciechanover is currently a distinguished research professor in the Rappaport Faculty of Medicine at the Technion – Israel Institute of Technology in Haifa, Israel, and serves on the board of several biotech companies. His current research is focused on several biological aspects of cancer development and tumor suppression, involving the role of the ubiquitin proteasome system in these processes. His laboratory, which is part of the Rappaport Technion’s Integrated Cancer Center (RTICC) in the Rappaport Faculty of Medicine, is currently involved in development of several anti-cancer drugs – including a unique PROTAC. It expands its areas of research and focus to include informatics, AI-based diagnoistic tools, and metabolomics, and in collaboration with Oncology Centers in Israel and China, initiating clinical trials that use application of precision medicine for the benefit of cancer patients.

Among the many accolades that Prof. Ciechanover has been awarded are the 2000 Albert Lasker Prize for Basic Medical Research, the 2003 Israel Prize for Biological Research, and the 2004 Nobel Prize in Chemistry. He is a member of various academies, including the Israeli National Academy of Sciences and Humanities, the European Molecular Biology Organization (EMBO), the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), and the Chinese Academy of Sciences (CAS; Foreign Member).

Robert Kerbel, PhD

Scientific Advisor
Prof. Robert Kerbel is a distinguished scientist at Sunnybrook Health Sciences Centre, University of Toronto, Canada. He is internationally recognized for his multiple contributions to cancer research, particularly in the fields of anti-angiogenic therapy and metronomic chemotherapy. For his achievements, Prof. Kerbel has been awarded the Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology, a Man of Distinction Honor by the Israel Cancer Research Fund, and the Colin Thomson Memorial Medal from Worldwide Cancer Research. He was a recipient of a tier 1 Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy from 2001-2015. Prof. Kerbel is a member of numerous scientific advisory boards in both industry and academia as well as scientific peer review journal editorial boards. He also holds multiple sponsored research agreements with biotech and pharmaceutical companies. Prof. Kerbel received his PhD in immunology from Queen’s University in Kingston, Ontario, Canada in 1972, and completed postdoctoral training in tumor immunology at the Chester Beatty Research Institute in London, England.

Raanan Berger, MD, PhD

Clinical Advisor
Prof. Raanan Berger is a senior oncologist and radiotherapist, serving as Director of the Cancer Center at the Sheba Medical Center, Israel. In 2006, he established the Riva Koschitzky Oncology Clinical Research Unit at Sheba, the largest center for all-phase oncology clinical trials in Israel, currently conducting over 200 advanced clinical trials. In addition, he is a senior lecturer at the Sackler Medical School at the Tel Aviv University, and runs a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis. Prof. Berger is a member of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), and co-author of over 70 peer reviewed scientific articles. He received his MD and PhD from the Sackler Faculty of Medicine at the Tel Aviv University, Israel, and was a post-doctoral fellow at Dana Farber Cancer Institute, Harvard Medical School.

David R. Gandara, MD

Clinical Advisor
Prof. David Gandara is the director of the Thoracic Oncology Program at the University of California Davis Comprehensive Cancer Center (UCDCCC), professor of medicine, and senior adviser to the cancer center director. Among the many honors that Prof. Gandara has been awarded are the IASLC Scientific Achievement Award, the Team Science Award from the Addario Lung Cancer Foundation and the Science Trajectory Award from the International Society of Liquid Biopsy, among others. Prof. Gandara is a co-leader at Lung-MAP, a precision medicine umbrella clinical trial for the development of biomarker-driven strategies for new therapies in lung cancer. His current research includes the development of preclinical modeling and clinical analysis in lung cancer. Recently, he was appointed Chief Medical Officer (CMO) of the International Society for Liquid Biopsy. Prior to his present roles, Prof. Gandara was president of the International Association for Study of Lung Cancer, as well as treasurer and BOD member of the American Society of Clinical Oncology (ASCO).

Eytan Domany, PhD

Statistical Advisor
Prof. Domany’s works in the faculty of Complex Systems Physics at the Weizmann Institute of Science. His expertise is in the field of statistical physics. His current research interests focus on the development of computational methods, with a special emphasis on applications to biologically motivated problems, in particular, analysis of high-throughput biological data. He works with several groups from the life sciences, in Israel and abroad, on analysis of human gene expression data obtained from DNA chips, with an emphasis on studies of cancer. Winner of the Lombroso Award in Cancer Research.

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
T. (855) 950-2112
E. [email protected]

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
T. +972 485 37558
E. [email protected]

Please Note:
PROphet® NSCLC is currently available in all US states except NY, PA, RI, and MD.